| Patent Number |
Title Of Patent |
Date Issued |
| RE36736 |
Substituted pyrroles |
June 13, 2000 |
| Compounds of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, X and Y have the signficance given in the description, are useful in the control or prevention of inflammatory, immunological, bronchopulmonary or cardiovascular disorders. |
| D305003 |
Chemistry analyzer tray |
December 12, 1989 |
|
| D305002 |
Chemistry analyzer tray |
December 12, 1989 |
|
| D305001 |
Chemistry analyzer tray |
December 12, 1989 |
|
| D288894 |
Safety bottle over-cap remover |
March 24, 1987 |
|
| 7456175 |
Piperazinyl-pyridine derivatives |
November 25, 2008 |
| The present invention relates to compounds of formula I ##STR00001## wherein R.sup.1, R.sup.2, X, Y, Z and m are as defined in the description and claims, and pharmaceutically acceptable salts thereof as well as to pharmaceutical composition comprising these compounds and to methods for |
| 7452909 |
Imidazole derivatives |
November 18, 2008 |
| The present invention relates to imidazole derivatives of formula I ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, X, Y and R are described hereinabove, or a pharmaceutically acceptable salt thereof. The invention also relates to a pharmaceutical composition comprising the |
| 7449483 |
Heteroaromate OSC inhibitors |
November 11, 2008 |
| The present invention relates to heteroaromate OSC inhibitors. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with 2,3-oxidosqualene-lanosterol cyclase such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, myc |
| 7446113 |
Acetylenyl-pyrazolo-pyrimidine derivatives |
November 4, 2008 |
| The present invention relates to compounds of formula (I): ##STR00001## wherein R.sup.1 to R.sup.3, A, M, L, E, G, and J are as defined in the description and claims. The invention also relates to a process for the manufacture of such compounds, pharmaceutical compositions containing |
| 7442710 |
Substituted phenyl methanones |
October 28, 2008 |
| The present invention relates to compounds of general formula IA or IB ##STR00001## wherein X.sup.1 and X.sup.2 are each independently N or C--R'' and R.sup.1, R.sup.2,R.sup.3, R.sup.4, R.sup.5, and R.sup.6 are as defined in the specification and to pharmaceutically acceptable acid |
| 7432291 |
Ether derivatives |
October 7, 2008 |
| The present invention provides the compounds of formula (I) ##STR00001## their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, compositions containing them and their manufacture, as well as |
| 7432256 |
Substitued imidazo [1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives |
October 7, 2008 |
| The present invention is concerned with substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives of the formula I ##STR00001## wherein R.sup.1 is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halo |
| 7423152 |
Process for the manufacture of intermediates in camptothecin production |
September 9, 2008 |
| The present invention provides a process for the manufacture of the compound of formula (1): ##STR00001## which is a key intermediate in the manufacture of camptothecin (CPT). This compound continues to serve as an attractive and promising lead structure for the development of new a |
| 7423060 |
Thiophene hydroxamic acid derivatives and their use as HDAC inhibitors |
September 9, 2008 |
| Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of th |
| 7417144 |
Factor Xa inhibitors |
August 26, 2008 |
| The invention is concerned with novel heteroaryl fused cyclic amines of formula (I) ##STR00001## wherein A, X.sup.1 to X.sup.3, Y.sup.1 to Y.sup.3, Z, R.sup.1, R.sup.2, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. |
| 7411093 |
Aminocycloalkanes as DPP-IV inhibitors |
August 12, 2008 |
| The present invention relates to compounds of formula (I) ##STR00001## wherein R.sup.1 is as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-I |
| 7407977 |
Substituted N-acyl-2-aminothiazoles |
August 5, 2008 |
| There are presented compounds of the formula ##STR00001## or a pharmaceutically acceptable salt thereof, which are useful in the treatment of diabetes, diabetic retinopathy, asthma and diarrhea. |
| 7405236 |
Indole derivatives comprising an acetylene group |
July 29, 2008 |
| This invention is directed to compounds of the formula (I): ##STR00001## wherein one of R.sup.6, R.sup.7, R.sup.8 and R.sup.9 is ##STR00002## and X, R.sup.1 to R.sup.12, m, n and o are as defined in the description, and pharmaceutically acceptable salts and/or esters thereof. The invent |
| 7390660 |
Methods for growing mammalian cells in vitro |
June 24, 2008 |
| The invention relates to a method for reducing glucose consumption during cultivation of animal cells, which comprises cultivating animal cells in the presence of a bi- or tricarbonic acid or a salt thereof at a concentration of about 1 to 50 mmol/l. |
| 7388025 |
3-aryl-isoxazole-4-carbonyl-benzofuran derivatives |
June 17, 2008 |
| The present invention is concerned with 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives of formula I ##STR00001## wherein R.sup.1, R.sup.2, and R.sup.3 are as defined in the specification and claims and with their pharmaceutically acceptable acid addition salts. These compounds |
| 7375226 |
Bi- and tricyclic substituted phenyl methanones |
May 20, 2008 |
| The present invention relates to compounds of formula IA ##STR00001## whereinR.sup.1, R.sup.2, R.sup.3, and n are as defined in the specification, and to pharmaceutically active acid addition salts thereof. The compounds of the invention are useful in the treatment of neurological an |
| 7371748 |
Benzothiazole derivatives |
May 13, 2008 |
| This invention relates to compounds of formula I ##STR00001## wherein R.sup.1 and R.sup.2 are defined herein, or a pharmaceutically acceptable salt thereof. It has been found that the compounds of formula I are adenosine receptor ligands with good affinity to the A.sub.2A-receptor |
| 7323466 |
Morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity |
January 29, 2008 |
| The present invention refers to chemical compounds of formula (I) ##STR00001## as well as pharmaceutically acceptable salts and esters thereof, wherein R.sup.1 to R.sup.5 have the significance given in claim 1. These compounds can be used for the preparation of medicaments. |
| 7317125 |
Diacylglycerol acyltransferase inhibitors |
January 8, 2008 |
| Provided herein are compounds of the formula (I): ##STR00001## as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment |
| 7268154 |
Substituted triazole compounds |
September 11, 2007 |
| The present invention relates to compounds of formula (I) ##STR00001## wherein R.sup.1, R.sup.2 and R.sup.3 are as defined in the specification and to pharmaceutically suitable acid addition salts thereof. The invention includes all sterioisomeric forms, including individual diastere |
| 7262303 |
Process for the production of chiral propionic acid derivatives |
August 28, 2007 |
| The present invention is concerned with a novel process for the preparation of compounds of formula I ##STR00001## comprising catalytic asymmetric hydrogenation of a compound of formula (II) ##STR00002## in the presence of a catalyst comprising ruthenium and a chiral diphosphine li |
| 7253318 |
Benzyloxy derivatives as MAOB inhibitors |
August 7, 2007 |
| The invention relates to compounds of the formula ##STR00001## and their pharmaceutically acceptable salts wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, n, m, and o are as defined in the specification. The compounds are selective monoamine oxidase .beta. inhibitors and are us |
| 7253282 |
Hexafluoroisopropanol substituted cyclohexane derivatives |
August 7, 2007 |
| The invention is concerned with novel hexafluoroisopropanol substituted cyclohexane derivatives of formula (I) ##STR00001## wherein R.sup.1 to R.sup.4, X, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These |
| 7250515 |
Thiazolinone 3,4-disubstituted quinolines |
July 31, 2007 |
| Thiazolinone disubstituted quinoline derivatives where the quinoline ring is disubstituted at the 3, 4 positions which derivatives demonstrate CDK1 antiproliferative activity and are useful as anti-cancer agents. |
| 7241893 |
Thiazolinone 2-substituted quinolines |
July 10, 2007 |
| Thiazolinone substituted quinoline derivatives where the quinoline ring is substituted at the 2 position which derivatives demonstrates CDK1 antiproliferative activity and are useful as anti-cancer agents. |
| 7235581 |
4-pyrrolidino-phenyl-benzyl ether derivatives |
June 26, 2007 |
| The invention relates to racemic or enantiomerically pure 4-pyrrolidino derivatives, processes for their preparation, pharmaceutical compositions comprising said derivatives, and their use in the prevention and treatment of illness, e.g. which are mediated by monoamine oxidase B inhi |
| 7235572 |
Thiazolyl-indole derivatives, their manufacture and use as pharmaceutical agents |
June 26, 2007 |
| This invention relates to compounds of the formula ##STR00001## wherein one of R.sup.6, R.sup.7 or R.sup.8 is ##STR00002## and all enantiomers and pharmaceutically acceptable salts and/or esters thereof as well as pharmaceutical compositions containing such compounds, to a process for |
| 7226923 |
Phthalazinone derivatives |
June 5, 2007 |
| Compounds of formula I ##STR00001## their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates are disclosed. Also disclosed are methods for the preparation of the above-mentioned compounds, pharmaceutical compositions containing them, as well as the |
| 7220744 |
Monocyclic substituted phenyl methanones |
May 22, 2007 |
| The present invention relates to compounds of formula I ##STR00001## wherein R.sup.1, R.sup.2, X.sup.1, and X.sup.2 are as defined in the specification and to pharmaceutically acceptable acid addition salts thereof. Such compounds are inhibitors of the glycine transporter 1 (GlyT-1) |
| 7202208 |
Erythropoietin composition |
April 10, 2007 |
| The present invention relates to a liquid pharmaceutical composition consisting essentially of an erythropoietin protein, a multiple charged inorganic anion in a pharmaceutically acceptable buffer suitable to keep the solution pH in the range from about 5.5 to about 7.0, and optionally |
| 7196234 |
Asymmetric reduction of 1,1,1-trifluoroacetone |
March 27, 2007 |
| The invention relates to a scalable biocatalytic process for the preparation of S-1,1,1-trifluoro-2-propanol with a enantiomeric excess of >99% by asymmetric microbial reduction of 1,1,1-trifluoroacetone with Baker's yeast. |
| 7189756 |
Pyrrolidine derivatives |
March 13, 2007 |
| The present invention relates to pyrrolidine derivatives useful as inhibitors of metalloproteases, e.g. zinc proteases, and which are effective in treating disease states associated with vasoconstriction. |
| 7189732 |
Pyrido[2,3-d]pyrimidine dichloro-phenyl derivatives |
March 13, 2007 |
| The invention describes compounds of the general formula I ##STR00001## a process for their manufacture, compositions containing them and their manufacture as well as the use of these compounds as pharmaceutically active agents. These compounds show activity as protein kinase inhibi |
| 7148229 |
Sulfonamide substituted xanthine derivatives |
December 12, 2006 |
| The present invention is a sulfonamide substituted xanthine derivative of formula I: ##STR00001## or a pharmaceutically acceptable salt thereof, wherein R1 is lower alkyl, lower alkyl substituted by phenyl, or lower alkyl substituted by halogen substituted phenyl; R2 is lower alkyl or |
| 7144890 |
Spiro-pentacyclic compounds |
December 5, 2006 |
| The present invention relates to compounds of the formula (I) ##STR00001## and pharmaceutically acceptable salts thereof, for use as therapeutically active substances. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation |
| 7144889 |
Triarylimidazoles |
December 5, 2006 |
| Compounds of the general formula (I) ##STR00001## are presented and are valuable therapeutics for the treatment of cancer and cancer related diseases. |
| 7091229 |
Tricyclic lactam and sultam derivatives and their use as histone deacetylase inhibitors |
August 15, 2006 |
| A compound of formula (I) ##STR00001## wherein A and B are optionally substituted cyclohexenyl or phenyl groups, X is carbonyl or sulfonyl, and Y is 5 7 atoms-linker, is useful as histone deacetylase inhibitors, particularly for inhibiting cell proliferation. |
| 7084270 |
Pyrimido compounds having antiproliferative activity |
August 1, 2006 |
| Disclosed are novel pyrimido compounds that are selective inhibitors of both KDR an FGFR kinases and are selective against LCK. These compounds and their pharmaceutically acceptable salts are anti-proliferative agents useful in the treatment or control of solid tumors, in particular brea |
| 7056932 |
Heterocyclyl substituted 1-alkoxy acetic acid amides |
June 6, 2006 |
| The invention is concerned with novel heterocyclyl substituted 1-alkoxy acetic acid derivatives of formula (I) ##STR00001## wherein R.sup.1 to R.sup.6 and A are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit |
| 7026456 |
Antibodies against human IL-12 |
April 11, 2006 |
| The present invention relates to novel p75 heterodimer specific anti-human IL-12 antibodies that are characterized by a higher potency and greater efficacy in neutralizing human IL-12 bioactivity than known heterodimer specific IL-12 monoclonal antibodies. The heterodimer specific antibo |
| 7022707 |
Piperazine derivatives |
April 4, 2006 |
| The present invention is a chemical compound of formula (I) ##STR00001## or a pharmaceutically acceptable salts, solvates and esters thereof, wherein R.sup.1 to R.sup.4, A.sup.1, A.sup.2 m and n are as described in the specification. |
| 7019001 |
Substituted benzothiazole amide derivatives |
March 28, 2006 |
| A compound of formula I and a method of treatment of diseases, related to modulation of the adenosine A.sub.2 receptor system comprising administering a compound of formula ##STR00001## to a person in need of such treatment. |
| 7005432 |
Substituted imidazol-pyridazine derivatives |
February 28, 2006 |
| The present invention relates to compounds of formula ##STR00001## wherein A is an unsubstituted or substituted cyclic group; and R is hydrogen or lower alkyl; or a pharmaceutically acceptable acid addition salt thereof.These compounds are NMDA NR-2B receptor subtype specific blocke |
| 6992083 |
Benzoxazol derivatives |
January 31, 2006 |
| The invention relates to compounds of formula ##STR00001## wherein R is phenyl, unsubstituted or substituted by halogen or --CH.sub.2N(CH.sub.3)(CH.sub.2).sub.nOCH.sub.3, or is benzyl, lower alkyl, lower alkoxy, --(CH.sub.2).sub.nOCH.sub.3, or is pyridin 3 -or 4-yl, unsubstitute |
| 6984744 |
Phosphine ligands |
January 10, 2006 |
| The invention is concerned with new phosphine ligands of formula I ##STR00001## wherein R.sup.1 and R.sup.2 are independently of each other unsubstituted alkyl, aryl, cycloalkyl or heteroaryl, or alkyl, aryl, cycloalkyl or heteroaryl each of which independently is substituted by alk |
